After 16 very long years without any truly viable treatment options for Alzheimer’s, there is some hope on the horizon, in a stunning reversal from the previously-rejected antibody therapy, aducanumab. The most recent research reveals that high doses of the medication do, in fact, lessen cognitive decline in the early stages of Alzheimer’s.
As stated by Rebecca Edelmayer, director of scientific engagement at the Alzheimer’s Association, “It could be a game-changer for the field. It could be one of the first disease-modifying therapies approved for Alzheimer’s disease.”
Biogen, the maker of aducanumab, estimates substantial benefits for dementia patients in a variety of aspects: activities of daily living, memory, language, and orientation. Biogen stated its plans to pursue regulatory approval within the United States, with a longer-term goal of launching the medication as an Alzheimer’s treatment option internationally.
With a forecasted request for approval from the FDA as soon as early 2020, the drug is slated to possibly end up becoming the first treatment method to actually lessen the clinical decline of Alzheimer’s. Moreover, it should open doors to many other treatment options that impact amyloid beta plaques, joining other trials that target the immune system, inflammation, blood vessels, and synaptic cell health. As seeking the most beneficial treatments for the disease is a challenging endeavor, it is probable that a combination of these treatments are likely to be essential, per Edelmayer.
The next challenge? Convincing the FDA to approve the drug after earlier failed trials. If approved, aducanumab will first be provided to people who had signed up for past trials, and hopefully, soon accessible to others dealing with all the problems of Alzheimer’s as well.
When it comes to the approximately 747,000 seniors in Canada fighting Alzheimer’s, and the families who care for them, these latest findings may very well be life-changing, as there are presently just minimally successful symptom-management medications available. As we await an effective Alzheimer’s treatment, we at Amy’s Helping Hands are able to assist dementia patients through highly skilled, trained, and qualified caregivers who draw on innovative therapeutic approaches that focus on each individual’s distinct strengths and making sure that each individual is living to the fullest.
For more information about excellent Alzheimer’s care that helps maximize total wellbeing while in the comfort of home, call Amy’s Helping Hands, the top providers of Windsor-Essex in-home care, at 519.915.4370 and ask for a consultation or additional helpful information.